eego Harbor, Michigan-based ZIVO Bioscience, Inc., a company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, has announced the execution of a letter of intent to produce its proprietary algae strain at Tianjin Norland Biotech (Norland) facilities in China. Norland is one of the largest producers of algae in China, and is among the first growers to be signed by ZIVO to supply dried biomass for a range of applications.
ZIVO anticipates that it will enter into a definitive, binding production agreement with Norland later in 2018. Norland is engaged in building a global supply chain to support anticipated demand for its algae-based feed, food and beverage ingredients. Over the past year, the company has been finalizing compliance and product formulation, positioning itself for a market introduction.
“The agreement in principle with Norland is a great start toward building global production capacity,” said Philip M. Rice, ZIVO’s Chief Financial Officer. “We’re committed to developing a base of high-quality producers that will help us meet market objectives.”
ZIVO Bioscience, Inc. is engaged in the investigation of the health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.